Growth • Supernus Pharmaceuticals
SUPN
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
11%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
-12,6%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
-8,2%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
-8,9%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
-10%
CAGR Normalized EPS 5Y
Normalized Earnings Per Share Compound Annual Growth Rate in the last 5 years.
3,7%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!